Andrea M Hall

US Patent:

6979446, Dec 27, 2005

Filed:

Jan 28, 2002

Appl. No.:

10/056052

Inventors:

Joseph M. Patti - Cumming GA, US
Jeff T. Hutchins - Cumming GA, US
Paul Domanski - Atlanta GA, US
Pratiksha Patel - Duluth GA, US
Andrea Hall - Acworth GA, US

Assignee:

Inhibitex, Inc. - Alpharetta GA

International Classification:

A61K039/395
A61K039/40
A61K039/085
C07K016/12
G01N033/569

US Classification:

424165, 4241301, 4241331, 4241641, 4241651, 4242371, 4242431, 435 733, 5303871, 5303884

Abstract:

Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from , including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.

US Patent:

7072887, Jul 4, 2006

Filed:

Apr 19, 2002

Appl. No.:

10/126053

Inventors:

Andrea M. Hall - Marietta GA, US
Camille Evans - Marietta GA, US
Ray B. Hollifield - Lawrenceville GA, US

Assignee:

Mirant Intellectual Asset Management and Marketing, LLC - Atlanta GA

International Classification:

G06F 17/30

US Classification:

707 4, 707 9, 707100, 707102

Abstract:

A system and method for identifying compatible associations between entities. The present invention stores data regarding compatibility factors for entities and provides searching capabilities on the data. In a preferred embodiment, the present invention identifies compatible matches for communities and companies. In this embodiment, the system stores industry data regarding the needs of the industries, and community data regarding the communities' resources for satisfying the respective needs of the industries. The system uses industry criteria, industry criterion weights, and industry criterion minimum levels to identify which community attributes are important to the particular industry. Communities are matched to companies within an industry through customized searches operable to identify communities which are compatible with certain industries or companies.

US Patent:

7115264, Oct 3, 2006

Filed:

Nov 5, 2002

Appl. No.:

10/287821

Inventors:

Joseph M. Patti - Cumming GA, US
Andrea Hall - Acworth GA, US
Paul Domanski - Atlanta GA, US
Peter Syribeys - Decatur GA, US
Jeff T. Hutchins - Cumming GA, US

Assignee:

INHIBITEX - Alpharetta GA

International Classification:

A61K 39/40

US Classification:

4241651, 4241301, 4241351, 4241411, 4241421, 4241501, 4242431, 435975, 435 71, 5303873, 5303871, 53038815, 5303881

Abstract:

Monoclonal antibodies which can bind to the Fnbp protein of and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. The monoclonal antibodies of the invention are advantageous in that they bind in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.

US Patent:

7364738, Apr 29, 2008

Filed:

May 25, 2005

Appl. No.:

11/136559

Inventors:

Joseph M. Patti - Cumming GA, US
Jeff T. Hutchins - Cumming GA, US
Paul Domanski - Atlanta GA, US
Pratiksha Patel - Duluth GA, US
Andrea Hall - Acworth GA, US

Assignee:

Inhibitex, Inc. - Alpharetta GA

International Classification:

A61K 39/00
A61K 39/395
A61K 39/40
C07K 16/00
C07K 16/12

US Classification:

4241651, 4241301, 4241331, 4241501, 4241641, 5303871, 5303873, 5303881, 5303884

Abstract:

Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from , including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.

US Patent:

8475798, Jul 2, 2013

Filed:

Jun 16, 2006

Appl. No.:

11/917435

Inventors:

Joseph M. Patti - Alpharetta GA, US
Jeff T. Hutchins - Cumming GA, US
Andrea Hall - Acworth GA, US
Linda Santos - San Antonio TX, US
Maria Bowden - Sugar Land TX, US
Magnus Hook - Houston TX, US

Assignee:

Inhibitex, Inc. - Alpharetta GA
The Texas A&M University System - College Station TX

International Classification:

A61K 39/40
A61K 39/00
A61K 39/395
G01N 33/569

US Classification:

4241501, 4241411, 4241421, 4241301, 4241391, 4241651, 435975, 435 733, 5303884, 5303881, 53038815

Abstract:

Monoclonal antibodies which can bind to the SdrF protein of are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of the SdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.

US Patent:

20040006209, Jan 8, 2004

Filed:

Mar 5, 2003

Appl. No.:

10/378674

Inventors:

Joseph Patti - Cumming GA, US
Jeff Hutchins - Cumming GA, US
Andrea Hall - Acworth GA, US
Paul Domanski - Atlanta GA, US
Pratiksha Patel - Marietta GA, US
Magnus Hook - Houston TX, US
Jeff Robbins - Alpharetta GA, US
John Vernachio - Canton GA, US
Maria Bowden - Sugarland TX, US

International Classification:

C07K001/00
C07K014/00
C07K017/00

US Classification:

530/350000

Abstract:

Monoclonal and polyclonal antibodies are provided which recognize and bind to the SdrG protein of , and more particularly to antibodies which recognize specific domains of the SdrG protein, namely the SdrG N1N2N3 protein (amino acids 50-597), the SdrG N2N3 protein (amino acids 273-597) and a truncated version of N2N3 identified as SdrG TR2 (amino acids 273-577). The antibodies of the invention, as well as pharmaceutical compositions incorporating these antibodies, are particularly useful in treating or preventing infections caused by coagulase-negative staphylococci